A streak of exciting new drug trials has helped Intermune triple in 2014. Can this biotech player give your portfolio a shot in the arm? Jim Cramer speaks with its …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More